4.4M+ patients have used our platform*
10K+ clinics globally in 30+ countries and 20+ languages*
200+ integrated devices
20+ clinical trials in 14 countries
Generating billions of patient moments and insights
Glooko takes it to the next level.
Making it easier than ever before for people with diabetes.
Glooko Secures $100 Million Series F Financing and
appoints Mike Alvarez as Chief Executive Officer
Glooko Secures $100 Million Series F Financing and
appoints Mike Alvarez as Chief Executive Officer
A new CEO for a new day at Glooko
After a global search, Glooko’s Board of Directors is delighted to announce Mike Alvarez as Chief Executive Officer. Mike brings Glooko more than 30 years of medical device experience and promises to bring his trademark energy, acumen, and results focused approach to moving Glooko even further into a marketplace of one.
I am thrilled to join Glooko at this pivotal moment in its journey. I look forward to continued commercial acceleration as we leverage real-world data to transform chronic condition management and improve enrollment and management in clinical trials through diverse and inclusive populations.
– Mike Alvarez
CEO, Glooko
New funding means new innovation.
As a part of our commitment to revolutionizing the lives of people living with diabetes and their teams, we’re excited to announce that Glooko has raised $100M in Series F funding. With that, Glooko is moving forward to transform diabetes care further.
Today, more than 537 million adults worldwide are diagnosed with diabetes, and the numbers are projected to grow every year. The need for timely, comprehensive and integrated support for healthcare practitioners is critical. Mike brings significant industry expertise, proven leadership and commercial success across chronic condition management. We believe Mike is the right leader at a key inflection point for Glooko and look forward to working with him.
– Simon Chong
Co-Founder, Georgian
Chairman, Glooko Board of Directors
*Number of clinics includes clinics using the Glooko® System, GlookoXT ®, and diasend® System since the respective launch of each product. Number of patients include patients over time who have used the Glooko® System, GlookoXT ®, and diasend® System since the respective launch of each product.
© 2024 Glooko, Inc. All rights reserved